Lupin's generic versions of the diabetes drugs Fortamet and Glumetza have boosted its sales in its largest market in the past year, but rival generics are expected to hit sales in the coming months, Managing Director Nilesh Gupta told Reuters.
To offset that, Lupin expects to launch about two dozen products in the fiscal year starting April 2017 in the United States, Gupta said on Thursday.
The company launched four products in the United States over the three months ended December. Lupin's sales in North America, which accounts for almost half of its overall revenue, rose nearly 58 percent in the quarter.
Like most of its peers, Lupin - the world's seventh-largest generic drugs maker - has been spending on building up its portfolio of niche products, such as respiratory devices, that are harder to make and therefore command higher prices and face limited competition. It is currently awaiting its first US approval for a metered-dose inhaler to treat asthma.
Earlier in the day, the Mumbai-based company reported a third-quarter net profit of Rs 633 crore, up from Rs 525 crore a year ago. Analysts on average expected a profit of Rs 629 crore, according to Thomson Reuters I/B/E/S.
The drugmaker's sales in India, its second-largest market, rose 12 percent from a year ago, but fell slightly versus the quarter ended September as distributors cut inventories after the government scrapped 500- and 1,000-rupee notes in November.
Gupta said sales at home are expected to recover by the first quarter of the coming financial year, and would grow at 15 percent each year "for the foreseeable future".
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.